Iberdomide
- Generic Name
- Iberdomide
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27N3O5
- CAS Number
- 1323403-33-3
- Unique Ingredient Identifier
- 8V66F27X44
- Background
Iberdomide (CC-220) has been used in trials studying the treatment of Systemic Lupus Erythematosus.
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Target Recruit Count
- 111
- Registration Number
- NCT06121843
- Locations
- 🇺🇸
Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota, United States
Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Daratumumab/rHuPH20 Co-formulation
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT06107738
- Locations
- 🇺🇸
KCI at McLaren Greater Lansing, Lansing, Michigan, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT05899738
- Locations
- 🇺🇸
Local Institution - 0001, Daytona Beach, Florida, United States
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients with Relapsed/Refractory Multiple Myeloma
- Conditions
- Refractory Multiple MyelomaRelapsed Multiple Myeloma
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Benjamin T Diamond, MD
- Target Recruit Count
- 30
- Registration Number
- NCT05896228
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1216
- Registration Number
- NCT05827016
- Locations
- 🇹🇷
Local Institution - 0068, Istanbul, Turkey
🇺🇸Rocky Mountain Cancer Centers, Aurora, Colorado, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT05583617
- Locations
- 🇦🇺
Prince of Wales Hospital, Randwick, New South Wales, Australia
🇫🇷IUCT Oncopole, Toulouse, France
🇫🇷Hopital Bretonneau, TOURS Cedex, France
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 7
- Registration Number
- NCT05560399
- Locations
- 🇺🇸
Icahn School of Medicine, New York, New York, United States
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 480
- Registration Number
- NCT05558319
- Locations
- 🇪🇸
Hospital Principe de Asturias, Alcalá de Henares, Madrid, Spain
🇪🇸Hospital Germans Trias i Pujol (ICO BADALONA), Badalona, Spain
🇪🇸Clinica Universidad Navarra (CUN), Pamplona, Navarra, Spain
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 140
- Registration Number
- NCT05527340
- Locations
- 🇪🇸
Hospital Universitario de Canarias, La Laguna, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Clínica Universidad de Navarra, Pamplona, Spain
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 80
- Registration Number
- NCT05434689
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Ohio State University Medical College, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.